The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial
Type
ArticleAuthor/s
Denholm, Justin T.Davis, Joshua
Paterson, David
Roberts, Jason
Morpeth, Susan
Snelling, Thomas
Zentner, Dominica
Rees, Megan
O'Sullivan, Matthew
Price, David
Bowen, Asha
Tong, Steven Y. C.
Abstract
Objectives: To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 infection.Objectives: To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 infection.
See less
See less
Date
2020Funding information
Health Research Council of New Zealand
Licence
OtherFaculty/School
Faculty of Medicine and Health, Sydney Medical SchoolShare